Related Experiment Video
Updated: Mar 18, 2026
Characterization of Complex Systems Using the Design of Experiments Approach: Transient Protein Expression in Tobacco as a Case Study
Published on: January 31, 2014
Advances and Further Comparison of Software Tools for Fisher Information Matrix-Based Design Evaluation in
Lucie Fayette1,2, Karl Brendel3, France Mentré4
1Université Paris Cité et Université Sorbonne Paris Nord, Inserm, IAME, F-75018 , Paris, France. lucie.fayette@inserm.fr.
Aim:
Before conducting a clinical study involving pharmacometrics analyses using Non-Linear Mixed Effects Models (NLMEM), study design can be evaluated by computing the Fisher Information Matrix (FIM) via first-order model linearisation. A 2015 study showed that several dedicated tools provided consistent results, with block-diagonal FIM approximations aligning more closely with clinical trial simulations (CTS) than full matrix approaches. Since, some tools have evolved with new features like covariate modelling and inter-occasion variability (IOV), while others have been newly developed within software initially created for parameter estimation in NLMEM. Our first aim is to compare predictions from both older (PFIM, PopED) and newer tools (NONMEM$Design, MlxDesignEval and Pumas OptimalDesign), and secondly to compare available estimation software to derived empirical predictions from CTS.
Methods:
The 2015 examples, involving an analytical pharmacokinetic (PK) model and a pharmacokinetic/pharmacodynamic model described by ODE, and new cases including a PK model with covariates and a cross over design with IOV were implemented in the five software. Predicted relative standard error (RSE) and D-criterion were computed. Empirical RSE and D-criterion were estimated from CTS with the different estimation tools.
Results:
For a given FIM approximation, both RSE and D-criterion were consistent across evaluation software. Results derived from block diagonal FIM were more aligned with CTS, for which results were comparable across estimation tools. Predictions were especially reliable for covariate effects and appropriately reflected the order of magnitude of IOV variances.
Conclusion:
Users can benefit from both reliable uncertainty prediction and parameter estimation regardless of their preferred software.
More Related Videos
06:00Optimization of the Epimedii Folium Mutton-Oil Processing Technology and Testing Its Effect on Zebrafish Embryonic Development
Published on: March 17, 2023
05:47In Silico Modeling Method for Computational Aquatic Toxicology of Endocrine Disruptors: A Software-Based Approach Using QSAR Toolbox
Published on: August 28, 2019
Related Concept Videos
01:12Analysis of Population Pharmacokinetic Data
01:12Statistical Software for Data Analysis and Clinical Trials
01:14Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
01:23Mechanistic Models: Compartment Models in Individual and Population Analysis
01:26Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
01:06Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...